03 June 2015
NovaMedica, casa farmaceutica russa, e Ferring Pharmaceuticals, gruppo biofarmaceutico globale con sede in Svizzera, hanno siglato un accordo che garantisce a NovaMedica una licenza di commercializzazione sul mercato russo dell'innovativa linea di farmaci gastroenterologici soggetti a prescrizione medica per la cura delle malattie infiammatorie intestinali (IBD).
02 June 2015
NovaMedica a Russian pharmaceutical company and Ferring Pharmaceuticals a Swiss-based global biopharmaceutical company have signed an agreement that gives NovaMedica the rights for commercialization of a range of Ferring’s line of innovative gastroenterological prescription drug products for the treatment of inflammatory bowel disease (IBD) in the Russian market.
Purple Day To Raise Epilepsy Awareness
31 March 2015
There is new hope for a recently discovered form of epilepsy that strikes only girls. It’s often misdiagnosed and difficult to treat. Thursday March 26th is designated as Purple Day to raise awareness about epilepsy.
Omega Pharma launches Benegast line in Russia
03 February 2015
Omega Pharma's Benegast portfolio of OTC gastrointestinal products is now available in Russia, after the Belgian firm signed a distribution agreement with NovaMedica.
29 January 2015
Russian pharmaceutical company NovaMedica and Omega Pharma, a Belgium-based pan-European pharmaceutical company specializing in the development and sale of over-the-counter (OTC) health and personal care products, have signed a partnership agreement granting NovaMedica exclusive rights to promote, distribute and sell a line of OTC gastrointestinal products under the BenegastTM umbrella brand in Russia.
29 January 2015
Das russische Pharmaunternehmen NovaMedica und der in Belgien ansässige paneuropäische Pharmakonzern Omega Pharma, der sich auf Entwicklung und Vertrieb rezeptfrei erhältlicher Gesundheits- und Körperpflegeprodukte konzentriert, haben eine Partnerschaftsvereinbarung unterzeichnet, gemäß der NovaMedica exklusive Rechte auf Bewerbung, Vertrieb und Verkauf einer Reihe rezeptfreier Magen-Darm-Produkte unter dem Dachmarkennamen BenegastTM in Russland erhält.
Oppenheimer Analyst Rohit Vanjani's 2015 Pipeline: Pot, Pain, and Babies
28 January 2015
Building on another blockbuster year in specialty pharmacy and generics, Rohit Vanjani, a senior analyst at Oppenheimer & Co., has reason to be excited for 2015. Vanjani specializes in nurturing firms developing novel ways to treat some of humanity's most persistent medical problems, and in this interview with The Life Sciences Report, he describes some of the most promising therapies, and companies, in the life sciences sector.
NovaMedica gets Russian rights for three gastrointestinal products from Omega Pharma
27 January 2015
NovaMedica and Belgian pharmaceutical firm Omega Pharma have signed a partnership agreement to promote, distribute and sell a line of OTC gastrointestinal products under Benegast brand in Russia.
Omega Pharma and NovaMedica to market a line of gastrointestinal products in Russia
23 January 2015
Russian pharmaceutical company NovaMedica and Omega Pharma, a Belgium-based pan-European pharmaceutical company specialising in the development and sale of over-the-counter (OTC) health and personal care products, have signed a partnership agreement granting NovaMedica exclusive rights to promote, distribute and sell a line of OTC gastrointestinal products under the Benegast umbrella brand in Russia.
23 January 2015
NovaMedica, ein russisches Pharmaunternehmen, und Ferring Pharmaceuticals, ein weltweit tätiges biopharmazeutisches Unternehmen mit Sitz in der Schweiz, haben einen Vertrag abgeschlossen, in dem NovaMedica die Rechte zur Vermarktung einer Reihe von innovativen verschreibungspflichtigen Magen-Darm-Medikamenten von Ferring auf dem russischen Markt erhält, die zur Behandlung chronisch-entzündlicher Darmerkrankungen (CED) eingesetzt werden.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024